Commercial CVS obesity drug deal puts Lilly on equal footing with Novo BioPharma DiveThe agreement includes Lilly s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.Metabolic & GLP-1Read full story pharminent May 28, 2026 (Last updated: May 28, 2026) BioPharma Dive The agreement includes Lilly s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk. Metabolic & GLP-1 Read full story Post navigation Previous: France ‘first EU country to cover obesity drugs’Next: GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’ Related Stories Commercial Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand pharminent September 14, 2026 Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026